|
|
|
|
Grannus BioSciences LTD • Privately held biotechnology company incorporated January 2004 under the Companies Acts in Scotland Registration Number SC240992 • Clinical stage novel anti-inflammatory products • Exclusive World Wide License from the University of Glasgow to issued and pending patents • Managed by Pharmetix Corp. of California, U.S.A. • Corporate Counsel, Dundas & Wilson, Glasgow www.grannusbiosciences.com
Grannus 2004-2005 • Grannus BioSciences Limited Announces Appointment of EGeen as CRO • Grannus BioSciences Ltd. Announces Agreement for Preclinical and Clinical Stage Molecules • Grannus receives a SCIS award from Targeting Innovation • Grannus to file IND/CTA for human clinical testing • Grannus receives Business Growth Fund Award from Scottish Enterprise • Grannus receives Notice of Allowance in Australia and China for its patent applications • Grannus appoints Iain McInnes and Robin Stevenson, Royal Infirmary Scotland and Dr. Minnie McMillan, USC School of Medicine to the Scientific Advisory Board
|
COMPANY OVERVIEW Grannus BioSciences Limited (GBL) is discovering and developing breakthrough bio-pharmaceuticals to combat inflammatory and hyperproliferative disorders. GBL’s efforts are focused on finding biologics and small molecule drugs that have the appropriate anti-inflammatory or anti-proliferative properties to regulate aberrant processes in the dermis, respiratory or gastrointestinal tract. The Company has several lead clinical stage products in development. The first is a phase II small molecule drug with application to the pre-malignant hyperproliferative condition known as Actinic Keratosis. The second is a Phase I biologic, thymosin beta 4 sulfoxide or TB4SO--a potent inhibitor of neutrophils-- formulated for dermatologic applications. The Company’s third product, GBL 101, is being developed to treat lung inflammation in COPD and Cystic Fibrosis or CF. In addition, Grannus has a pipeline of preclinical molecules that are also being developed for additional inflammatory applications. Grannus seeks strategic alliances and partnerships that will support the global commercialization of its products. The Company plans to out-license rights to its product opportunities at Phase I or II to a partner in the major territories (North America, Europe, or Japan), while retaining rights in the rest of the world. Grannus also is looking to in-license additional products for development. |
|